TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11158556

Group type: EXPERIMENTAL
Intervention: Various interventions in pregnancy/perinatal medicine
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Various interventions in myocardial infarction
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Magnesium in myocardial infarction
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Calcium for prevention of pre-eclampsia
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents for prevention of pre-eclampsia
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Other unspecified interventions
Number of subjects: 2000
Study: 9732932

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 7994946

Group type: EXPERIMENTAL
Intervention: Bilateral total knee arthroplasty with femoral canal decompression using an overdrilled entrance hole and fluted guide rod
Number of subjects: 35

Group type: COMPARATOR
Intervention: Unilateral total knee arthroplasty
Number of subjects: 35
Study: 2525996

Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg BID)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Aztreonam (for pyelonephritis)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Norfloxacin (for pyelonephritis)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Aztreonam (for cystitis)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Norfloxacin (for cystitis)
Number of subjects: 82
Study: 26983904

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Child-Centered Therapy (CCT)
Number of subjects: 133
Study: 28753932

Group type: EXPERIMENTAL
Intervention: Red ginseng (3000 mg/day) for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25467231

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 30

Group type: COMPARATOR
Intervention: CH
Number of subjects: 30
Study: 23979005

Group type: EXPERIMENTAL
Intervention: Behavioral weight gain prevention intervention (medium-intensity) including tailored behavior change goals, weekly self-monitoring via interactive voice response, monthly counseling calls, tailored skills training materials, and a gym membership.
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Behavioral weight gain prevention intervention (medium-intensity)
Number of subjects: 194
Study: 21782874

Group type: EXPERIMENTAL
Intervention: rHPIV3cp45 vaccine (10^5 TCID50 dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19035501

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,000 mg of calcium and 400 IU of vitamin D)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo (with 400 IU of vitamin D)
Number of subjects: 198
Study: 16798389

Group type: EXPERIMENTAL
Intervention: Streptokinase and aspirin plus bivalirudin
Number of subjects: 15222

Group type: COMPARATOR
Intervention: No initial Q waves
Number of subjects: 15222
Study: 12672184

Group type: EXPERIMENTAL
Intervention: Ro 45‐2081 (low dose 0.05 mg/kg, maximum 5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ro 45‐2081 (mid-dose 0.2 mg/kg, maximum 20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ro 45‐2081 (high dose 0.5 mg/kg, maximum 50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9658758

Group type: EXPERIMENTAL
Intervention: High-frequency (20 MHz) ultrasound probe (HFUP)
Number of subjects: 27
Study: 8704438

Group type: EXPERIMENTAL
Intervention: Yangxueshengru Oral Liquor (YXSR)
Number of subjects: 103
Study: 2666884

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of 2 g cefotetan
Number of subjects: 75

Group type: COMPARATOR
Intervention: Triple dose of 1 g intravenous cephazolin
Number of subjects: 75
Study: 338399

Group type: EXPERIMENTAL
Intervention: Maprotiline (Ludiomil)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 75
Study: 30457349

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 160
Study: 28724846

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily for nine months)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 or 15 mg once daily for nine months)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both Orlistat and Sibutramine
Number of subjects: 76
Study: 24300630

Group type: EXPERIMENTAL
Intervention: 10-day sequential treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: 10-day conventional treatment
Number of subjects: 71
Study: 21786524

Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin
Number of subjects: 74

Group type: COMPARATOR
Intervention: 75 mg pregabalin
Number of subjects: 74

Group type: COMPARATOR
Intervention: 150 mg pregabalin
Number of subjects: 74

Group type: COMPARATOR
Intervention: 7.5 mg midazolam (placebo)
Number of subjects: 74
Study: 19208256

Group type: EXPERIMENTAL
Intervention: Conditional Random Fields (CRFs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support Vector Machines
Number of subjects: 0
Study: 17924845

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Immediate curative therapy without CAB (Group I)
Number of subjects: 54
Study: 15083959

Group type: EXPERIMENTAL
Intervention: Daily OL-HDF (2 to 2.5 hours, six times per week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thrice weekly OL-HDF (4 to 5 hours) - Control group
Number of subjects: 24
Study: 11219483

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 5-day
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 7-day
Number of subjects: 527

Group type: COMPARATOR
Intervention: Clarithromycin 10-day
Number of subjects: 527
Study: 9831631

Group type: EXPERIMENTAL
Intervention: MTP polymorphisms (MTP/-400 (A->t) and MTP/-164 (T->c))
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Patients with MI
Number of subjects: 1350
Study: 7926056

Group type: EXPERIMENTAL
Intervention: Haemoccult screening without dietary restrictions
Number of subjects: 153

Group type: COMPARATOR
Intervention: Haemoccult screening with dietary restrictions
Number of subjects: 153
Study: 1736162

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 410205

Group type: EXPERIMENTAL
Intervention: haptoglobin type hp 1-1
Number of subjects: 167

Group type: COMPARATOR
Intervention: haptoglobin types hp 2-1 and hp 2-2
Number of subjects: 167
Study: 31376516

Group type: EXPERIMENTAL
Intervention: Tendon of deer liquid (TD) supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24861696

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW/QW
Number of subjects: 748

Group type: COMPARATOR
Intervention: Etanercept 50 mg QW/QW
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 748
Study: 24169302

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (3.5 mL of autologous platelets buffered with 8.4% sodium bicarbonate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC) injection (1 mL triamcinolone, 40 mg/mL + 2 mL lidocaine, 10 mg/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline injection (3 mL saline, 0.9%)
Number of subjects: 60
Study: 20880292

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 IU/kg)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (high level)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Vitamin E and vaccination routine interaction
Number of subjects: 720
Study: 19164620

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL) and Macintosh laryngoscope
Number of subjects: 41

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 41
Study: 16717305

Group type: EXPERIMENTAL
Intervention: Continuous remifentanil infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intermittent morphine alone
Number of subjects: 30
Study: 16935471

Group type: EXPERIMENTAL
Intervention: Topical application of 3% VC-IP cream for 3 weeks
Number of subjects: 0
Study: 12711233

Group type: EXPERIMENTAL
Intervention: Wavelet analysis of EMG signals from two different shoulder muscles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local intermittency measure
Number of subjects: 0
Study: 10598693

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (COSOPT) twice daily
Number of subjects: 253

Group type: COMPARATOR
Intervention: Timolol (TIMOPTIC) twice daily
Number of subjects: 253

Group type: COMPARATOR
Intervention: Dorzolamide (TRUSOPT) three times daily
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Combination (COSOPT)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Dorzolamide (TRUSOPT)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Timolol (TIMOPTIC)
Number of subjects: 253
Study: 8524486

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (mean resting blood pressure > 107 mmHg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normotensive patients (mean resting blood pressure ≤ 107 mmHg)
Number of subjects: 74
Study: 2287795

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7000061

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31586510

Group type: EXPERIMENTAL
Intervention: Health warning arm (sugar-sweetened beverages displayed a front-of-package health warning)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control arm (sugar-sweetened beverages displayed a control label)
Number of subjects: 400
Study: 29255098

Group type: EXPERIMENTAL
Intervention: Probiotic capsules (24 × 10^9 colony-forming units of lactobacilli and bifidobacteria)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: No chewing gum
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Sorbitol gum (5 pieces daily)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Xylitol gum (15% xylitol; 5 pieces daily)
Number of subjects: 1009
Study: 25854191

Group type: EXPERIMENTAL
Intervention: Mesalt combined with Mepilex dressing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional gauze dressing
Number of subjects: 60
Study: 23297867

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Concerta®), up-titrated over 2 weeks to a maximum dose of 54 mg daily for 20 weeks, given under daily supervision.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo, administered under the same conditions as methylphenidate.
Number of subjects: 79
Study: 21894705

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Neimadian(Extra)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) with Sufentanil
Number of subjects: 120
Study: 19850248

Group type: EXPERIMENTAL
Intervention: Reduced-dose reteplase + abciximab
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Abciximab alone
Number of subjects: 2452

Group type: COMPARATOR
Intervention: Placebo (abciximab in the cath lab)
Number of subjects: 2452
Study: 17234657

Group type: EXPERIMENTAL
Intervention: High-selenium yeast preparation (100 microg daily, n=99)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo (yeast only, n=98)
Number of subjects: 197
Study: 15293890

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day) and veralipride (100 mg/day) on alternate days (n = 17)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day) and veralipride (100 mg/day) on alternate months (n = 12)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Raloxifene and veralipride (both protocols)
Number of subjects: 29
Study: 11380743

Group type: EXPERIMENTAL
Intervention: Nurse-led interdisciplinary intervention program for delirium
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care/nonintervention cohort
Number of subjects: 120
Study: 9403933

Group type: EXPERIMENTAL
Intervention: Topical dinitrochlorobenzene (DNCB) therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no DNCB therapy)
Number of subjects: 8
Study: 8389106

Group type: EXPERIMENTAL
Intervention: MK-679 500 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MK-679 125 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3549028

Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.05 mg X kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 31551217

Group type: EXPERIMENTAL
Intervention: Ticagrelor treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: Clopidogrel treatment (Control)
Number of subjects: 74
Study: 28221247

Group type: EXPERIMENTAL
Intervention: eHealth intervention using the web-application young.constant-care.com (YCC) on a monthly basis and during flare-ups, with annual outpatient visits.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: eHealth intervention
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group with standard visits every third month.
Number of subjects: 53
Study: 26395762

Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: PCA
Number of subjects: 120
Study: 23771826

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo Kinesio taping
Number of subjects: 27

Group type: COMPARATOR
Intervention: Without taping
Number of subjects: 27
Study: 21811172

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 19622902

Group type: EXPERIMENTAL
Intervention: Cetuximab treatment
Number of subjects: 933
Study: 16677182

Group type: EXPERIMENTAL
Intervention: Oral functional training plus high-calorie and high-protein diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-calorie and high-protein diet (supplement group)
Number of subjects: 14
Study: 15290410

Group type: EXPERIMENTAL
Intervention: Epinephrine group (n = 10) received 14 mg of tetracaine and 0.2 mg of epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10) received 14 mg of tetracaine
Number of subjects: 20
Study: 12175355

Group type: EXPERIMENTAL
Intervention: New information leaflet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Old information leaflet
Number of subjects: 100
Study: 9666867

Group type: EXPERIMENTAL
Intervention: GH therapy (0.25 IU/kg/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (first 6 months) then switched to GH therapy
Number of subjects: 20
Study: 8120554

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) starting on day 6 with 5-FU/LCV
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) starting on day 1 with 5-FU/LCV
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 37
Study: 2803050

Group type: EXPERIMENTAL
Intervention: Piracetam 8 g
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 53553

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 with hypertonic urea
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 with hypertonic glucose
Number of subjects: 27

Group type: COMPARATOR
Intervention: Prostaglandin E2 alone
Number of subjects: 27
Study: 31017470

Group type: EXPERIMENTAL
Intervention: Pentraxin 3
Number of subjects: 5154

Group type: EXPERIMENTAL
Intervention: Pentraxin 3 measured in the chronic phase (one month)
Number of subjects: 5154
Study: 31265972

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 172
Study: 29016646

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 71
Study: 26180352

Group type: EXPERIMENTAL
Intervention: Flexion-distraction manipulation therapy combined with conservative physical therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conservative physical therapy
Number of subjects: 30
Study: 23520169

Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation (MECC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 200
Study: 21468387

Group type: EXPERIMENTAL
Intervention: Percutaneous osteotomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endonasal osteotomy
Number of subjects: 20
Study: 19361723

Group type: EXPERIMENTAL
Intervention: Self-ligating (SL) brackets
Number of subjects: 26

Group type: COMPARATOR
Intervention: Elastomeric (E) brackets
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ATP-driven bioluminescence
Number of subjects: 26
Study: 16736519

Group type: EXPERIMENTAL
Intervention: Baseline OPG:RANKL ratio
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: First-year time-averaged erythrocyte sedimentation rate (tESR)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High tESR and low OPG:RANKL ratio
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low tESR and high OPG:RANKL ratio
Number of subjects: 92
Study: 15047788

Group type: EXPERIMENTAL
Intervention: Experience Corps program
Number of subjects: 0
Study: 10754625

Group type: EXPERIMENTAL
Intervention: EMLA cream and plastic occlusive dressing
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Placebo cream and plastic occlusive dressing
Number of subjects: 202

Group type: COMPARATOR
Intervention: Nothing on the skin (control)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Plastic occlusive dressing
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: EMLA cream and plastic occlusive dressing for 60 min
Number of subjects: 202
Study: 8970892

Group type: COMPARATOR
Intervention: Single oral phosphate dose (1500 mg in water)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Three consecutive oral phosphate doses (3 x 500 mg in water)
Number of subjects: 10
Study: 1728934

Group type: EXPERIMENTAL
Intervention: 1200 mg gemfibrozil (two 300 mg capsules twice daily)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 600 mg gemfibrozil (one 600 mg tablet twice daily)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 900 mg gemfibrozil (two 450 mg tablets in the evening)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: gemfibrozil (all formulations)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 900 mg gemfibrozil
Number of subjects: 322
Study: 6365235

Group type: EXPERIMENTAL
Intervention: Oral amoxycillin (3 g) and clavulanate (250 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intramuscular procaine penicillin (2.4 MU)
Number of subjects: 121
Study: 29987586

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model, delivered in eight sessions.
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model.
Number of subjects: 480
Study: 28658491

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 2032
Study: 26717223

Group type: EXPERIMENTAL
Intervention: 60-mg prasugrel loading dose
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clopidogrel standard dose
Number of subjects: 50
Study: 23109650

Group type: EXPERIMENTAL
Intervention: Heart failure management programme (HFMP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no HFMP)
Number of subjects: 160
Study: 21800004

Group type: EXPERIMENTAL
Intervention: 1g/day n3‐PUFA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 4 g/day n3‐PUFA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: n3‐PUFA
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19501883

Group type: EXPERIMENTAL
Intervention: Doxazosin plus tenoxicam 20 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Doxazosin 4 mg
Number of subjects: 57
Study: 16716975

Group type: EXPERIMENTAL
Intervention: 24 months interval between surveillance colonoscopies (group A)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: 48 months interval between surveillance colonoscopies (group B)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: 6 months interval between surveillance colonoscopies (group C)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: 12 months interval between surveillance colonoscopies (group D)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: 12 months interval between surveillance colonoscopies (group E)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: 24 months interval between surveillance colonoscopies (group F)
Number of subjects: 944
Study: 15033094

Group type: EXPERIMENTAL
Intervention: Hypertension (HT)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia (HCOL)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Tobacco dependency
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Association of CVRF
Number of subjects: 2550
Study: 10681323

Group type: EXPERIMENTAL
Intervention: Lamivudine 0.35 mg/kg twice daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lamivudine 1.5 mg/kg twice daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lamivudine 4 mg/kg twice daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lamivudine 3 mg/kg once daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg (tablets) for adolescents
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lamivudine (all doses)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lamivudine 3 mg/kg/day
Number of subjects: 53
Study: 9316958

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (1 mg/kg)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Caudal analgesia (1 ml/kg 0.20% bupivacaine with 1/200,000 epinephrine)
Number of subjects: 164